Patent · US Active

Heterocyclic compound

US11230541B2 · kind B2 · utility

2Cited by

3References

12Claims

0Family size

Assignee

Takeda Pharmaceutical Company Limited · JP

Inventors

Eiji KIMURA · Yokohama, JP
Masaki Ogino · Yokohama, JP
Yasuhisa Kohara · Yokohama, JP
Tomoko Ohashi · Yokohama, JP
Tomohiro Kaku · Nishinomiya, JP
Yuya Oguro · Yokohama, JP
Shigemitsu Matsumoto · Yokohama, JP
Takeshi Wakabayashi · Fujisawa, JP
Norihito Tokunaga · Fujisawa, JP
Taku Kamei · Fujisawa, JP
Mitsuhiro Ito · Yokohama, JP

Key dates

Filing date	Jul 26, 2018
Grant date	Jan 25, 2022
Priority date	—
Expiry date	Jul 26, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D401/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.